Divyaveer SS, Ramachandran R, Sahay M, et al. International society of nephrology global kidney health atlas: structures, organization, and services for managing kidney failure in South Asia. Kidney Int Suppl. 2021;11:e97–105.

Varughese S, Abraham G. Chronic kidney disease in india: a clarion call for change. Clin J Am Soc Nephrol. 2018;13:802–4.

Goel A, Rewari BB, Sharma M, Konath NM, Aggarwal R. Seroprevalence and burden of hepatitis C virus infection in WHO Southeast Southeast Asia Region: a systematic review. J Gastroenterol Hepatol. 2022;37:964–72.

Article  PubMed  Google Scholar 

Goel A, Seguy N, Aggarwal R. Burden of hepatitis C virus infection in India: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2019;34:321–9.

Goel A, Bhadauria DS, Kaul A, et al. Acute hepatitis C treatment in advanced renal failure using eight weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. Nephrol Dial, Transplant. 2021;36:1867–71.

Goel A, Bhadauria DS, Kaul A, et al. Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min. Nephrology (Carlton). 2019;24:316–21.

Fabrizi F, Cerutti R, Donato FM, Messa P. HBV infection is a risk factor for chronic kidney disease: systematic review and meta-analysis. Rev Clin Esp (Barc). 2021;221:600–11.

Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:1526–33.

Johnson DW, Dent H, Yao Q, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009;24:1598–603.

Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis. 2020;75:417–25.

Guidelines for vaccination in patients with chronic kidney disease. Indian J Nephro. 2016;26 Supplement 1:S15–S8.

World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. Vaccine. 2019;37:223–5.

DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42:1184–92.

Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodial Int. 2005;9:367–75.

Article  PubMed  Google Scholar 

Mulley WR, Le ST, Ives KE. Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32:136–43.

Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepat Mon. 2012;12:e7359.

Fabrizi F, Martin P, Messa P. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs. 2015;38:625–31.

Article  PubMed  Google Scholar 

Janssen JM, Heyward WL, Martin JT, Janssen RS. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Vaccine. 2015;33:833–7.

Article  CAS  PubMed  Google Scholar 

Girndt M, Houser P, Manllo-Karim R, et al. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease. Vaccine. 2023;41:3224–32.

Manley HJ, Aweh G, Frament J, Ladik V, Lacson EK. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis. Nephrol Dial Transplant. 2023;38:447–54.

Vesikari T, Finn A, van Damme P, et al. Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial. JAMA Netw Open. 2021;4:e2128652.

Krairittichai U, Sethakarun S. A randomized controlled trial of seroconversion after 20 mg versus 40 mg intramuscular hepatitis B virus vaccination in patients with chronic kidney disease stage 3. J Med Assoc Thai. 2017;100 Suppl 1 :S1-7.

PubMed  Google Scholar 

Ahmadi F, Ramezani M, Razeghi E, Ranjbarnovin N, Khazaeipour Z. A randomized controlled trial of two schedules of hepatitis B vaccination in predialysed chronic renal failure patients. Hepat Mon. 2012;12:344–8.

Article  PubMed  PubMed Central  Google Scholar 

Fan W, Chen XF, Shen C, Guo ZR, Dong C. Hepatitis B vaccine response in obesity: a meta-analysis. Vaccine. 2016;34:4835–41.

Patel N, Assimon MM, Bruni E, McNutt LA, Mason DL. Incidence and clinical predictors of nonresponse to hepatitis B vaccination among patients receiving hemodialysis: importance of obesity. South Med J. 2015;108:567–73.

Article  CAS  PubMed  Google Scholar 

Ma BM, Yap DYH, Yip TPS, Hung IFN, Tang SCW, Chan TM. Vaccination in patients with chronic kidney disease-review of current recommendations and recent advances. Nephrology (Carlton). 2021;26:5–11.

Article  PubMed  Google Scholar 

Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD stages 3–4 and hemodialysis patients. J Res Med Sci. 2012;17:527–33.

PubMed  PubMed Central  Google Scholar 

Al Saran K, Sabry A, Al Halawany Z, Ismail M. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl. 2014;25:185–91.

Article  PubMed  Google Scholar 

Asan A, Demirhan H, Sorkun HC, et al. Factors affecting responsiveness to hepatitis B immunization in dialysis patients. Int Urol Nephrol. 2017;49:1845–50.

Malaki M. Factors affecting on hepatitis B seroprotection in hemodialysis patients. Saudi J Kidney Dis Transpl. 2017;28:672–4.

Article  PubMed  Google Scholar